Geneos Wealth Management Inc. Sells 4,750 Shares of Insulet Corporation $PODD

Geneos Wealth Management Inc. lowered its stake in shares of Insulet Corporation (NASDAQ:PODD) by 13.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,174 shares of the medical instruments supplier’s stock after selling 4,750 shares during the quarter. Geneos Wealth Management Inc.’s holdings in Insulet were worth $6,542,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC lifted its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet in the 4th quarter worth $26,000. DV Equities LLC purchased a new stake in shares of Insulet in the fourth quarter valued at about $28,000. Elyxium Wealth LLC purchased a new stake in shares of Insulet in the fourth quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. bought a new position in shares of Insulet during the fourth quarter valued at about $29,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Multiple law firms issued reminders and investor alerts about a securities class action against Insulet, with lead-plaintiff deadlines set for August 31, 2026. These notices generally keep the stock in the spotlight but do not by themselves change the underlying case. Article link
• Neutral Sentiment: Another law firm announced that a class action lawsuit has been filed against Insulet and certain officers on behalf of investors who bought shares during the alleged class period, reinforcing concerns about legal overhang for the company. Article link
• Neutral Sentiment: Prior reporting cited allegations that two Omnipod corrections may have exposed broader quality-control issues and contributed to a sharp earlier selloff, which helps explain why litigation-related headlines remain a focus for traders. Article link

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PODD. Bank of America lowered their price objective on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Leerink Partners reduced their target price on shares of Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Wells Fargo & Company decreased their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Stifel Nicolaus lowered their price target on shares of Insulet from $250.00 to $225.00 and set a “buy” rating on the stock in a report on Friday, July 10th. Finally, Barclays dropped their price objective on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research note on Thursday, May 7th. Twenty-two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.25.

Insulet Stock Performance

NASDAQ PODD opened at $164.43 on Friday. The company’s 50 day moving average is $152.81 and its 200-day moving average is $207.20. Insulet Corporation has a 12-month low of $138.79 and a 12-month high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The firm has a market cap of $11.39 billion, a P/E ratio of 38.24, a price-to-earnings-growth ratio of 1.11 and a beta of 1.11.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the prior year, the company posted $1.02 EPS. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts predict that Insulet Corporation will post 6.45 earnings per share for the current year.

Insider Activity

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.36% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.